{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T22:59:03Z","timestamp":1780613943539,"version":"3.54.1"},"reference-count":48,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Revista Espa\u00f1ola de Medicina Nuclear e Imagen Molecular (English Edition)"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.remnie.2025.500162","type":"journal-article","created":{"date-parts":[[2025,5,20]],"date-time":"2025-05-20T11:56:13Z","timestamp":1747742173000},"page":"500162","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Revolutionizing prostate cancer treatment: PSMA-targeted therapy in modern therapeutics"],"prefix":"10.1016","volume":"44","author":[{"given":"A.","family":"Ricaurte-Fajardo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Marulanda-Corzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Ruder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.R.","family":"Cardoza-Ochoa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.E.","family":"Granados","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Yadav","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"L\u00f3pez-Delgado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Fatima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Dutruel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"O\u2019Dwyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.R.","family":"Osborne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.T.","family":"Tagawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Huicochea Castellanos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.remnie.2025.500162_bib0005","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/S1470-2045(03)01138-0","article-title":"Prostate cancer: a dynamic illness with shifting targets","volume":"4","author":"Shaffer","year":"2003","journal-title":"Lancet Oncol."},{"issue":"11","key":"10.1016\/j.remnie.2025.500162_bib0010","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1111\/j.1742-1241.2011.02799.x","article-title":"Characterising the castration-resistant prostate cancer population: a systematic review","volume":"65","author":"Kirby","year":"2011","journal-title":"Int J Clin Pract"},{"issue":"3","key":"10.1016\/j.remnie.2025.500162_bib0015","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin."},{"issue":"7","key":"10.1016\/j.remnie.2025.500162_bib0020","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1200\/JCO.2007.12.4487","article-title":"Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the prostate cancer clinical trials Working Group","volume":"26","author":"Scher","year":"2008","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol."},{"key":"10.1016\/j.remnie.2025.500162_bib0025","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.canlet.2022.01.028","article-title":"Racial disparities in prostate cancer: a complex interplay between socioeconomic inequities and genomics","volume":"531","author":"Lowder","year":"2022","journal-title":"Cancer Lett."},{"issue":"17","key":"10.1016\/j.remnie.2025.500162_bib0030","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.0502101102","article-title":"Crystal structure of prostate-specific membrane antigen, a tumor marker and peptidase","volume":"102","author":"Davis","year":"2005","journal-title":"Proc Natl Acad Sci."},{"issue":"1","key":"10.1016\/j.remnie.2025.500162_bib0035","doi-asserted-by":"crossref","first-page":"158","DOI":"10.3390\/diagnostics13010158","article-title":"PSMA receptor-based PET-CT: the basics and current status in clinical and research applications","volume":"13","author":"Adnan","year":"2023","journal-title":"Diagnostics."},{"issue":"2","key":"10.1016\/j.remnie.2025.500162_bib0040","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1007\/s13139-014-0315-z","article-title":"Production of 177Lu for targeted radionuclide therapy: available options","volume":"49","author":"Dash","year":"2015","journal-title":"Nucl Med Mol Imaging."},{"issue":"9","key":"10.1016\/j.remnie.2025.500162_bib0045","doi-asserted-by":"crossref","DOI":"10.1158\/1078-0432.CCR-22-2875","article-title":"FDA approval summary: lutetium Lu 177 vipivotide tetraxetan for patients with metastatic castration-resistant prostate cancer","volume":"29","author":"Fallah","year":"2023","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res."},{"issue":"4","key":"10.1016\/j.remnie.2025.500162_bib0050","doi-asserted-by":"crossref","first-page":"701","DOI":"10.34172\/apb.2023.079","article-title":"Lutetium-177-labeled prostate-specific membrane antigen-617 for molecular imaging and targeted radioligand therapy of prostate cancer","volume":"13","author":"Ritawidya","year":"2023","journal-title":"Adv Pharm Bull"},{"issue":"5","key":"10.1016\/j.remnie.2025.500162_bib0055","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1007\/s11912-021-01042-w","article-title":"Prostate-Specific Membrane Antigen (PSMA)-targeted radionuclide therapies for prostate cancer","volume":"23","author":"Sun","year":"2021","journal-title":"Curr Oncol Rep."},{"issue":"6","key":"10.1016\/j.remnie.2025.500162_bib0060","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/S1470-2045(18)30198-0","article-title":"[177Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study","volume":"19","author":"Hofman","year":"2018","journal-title":"Lancet Oncol."},{"issue":"10276","key":"10.1016\/j.remnie.2025.500162_bib0065","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/S0140-6736(21)00237-3","article-title":"[177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial","volume":"397","author":"Hofman","year":"2021","journal-title":"Lancet."},{"issue":"4","key":"10.1016\/j.remnie.2025.500162_bib0070","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1016\/j.eururo.2023.12.004","article-title":"Safety analyses of the phase 3 VISION trial of [177Lu]Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer","volume":"85","author":"Chi","year":"2024","journal-title":"Eur Urol."},{"key":"10.1016\/j.remnie.2025.500162_bib0075","doi-asserted-by":"crossref","DOI":"10.1016\/j.annonc.2021.08.1113","article-title":"600P Final results of phase I\/II trial of fractionated dose 177Lu-PSMA-617 for metastatic castration-resistant prostate cancer (mCRPC)","volume":"32","author":"Tagawa","year":"2021","journal-title":"Ann Oncol."},{"issue":"4","key":"10.1016\/j.remnie.2025.500162_bib0080","doi-asserted-by":"crossref","DOI":"10.1148\/rycan.229016","article-title":"LuPIN substudy of posttreatment PET after 177Lu-PSMA-617 with NOX66: prognostic value of FDG and PSMA","volume":"4","author":"Burkett","year":"2022","journal-title":"Radiol Imaging Cancer"},{"key":"10.1016\/j.remnie.2025.500162_bib0085","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2022.40.16_suppl.5017","article-title":"PRINCE: phase I trial of 177Lu-PSMA-617 in combination with pembrolizumab in patients with metastatic castration-resistant prostate cancer (mCRPC)","volume":"40","author":"Sandhu","year":"2022","journal-title":"J Clin Oncol."},{"issue":"5","key":"10.1016\/j.remnie.2025.500162_bib0090","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/S1470-2045(24)00135-9","article-title":"[177Lu]Lu-PSMA-617 plus enzalutamide in patients with metastatic castration-resistant prostate cancer (ENZA-p): an open-label, multicentre, randomised, phase 2 trial","volume":"25","author":"Emmett","year":"2024","journal-title":"Lancet Oncol."},{"issue":"6_suppl","key":"10.1016\/j.remnie.2025.500162_bib0095","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2023.41.6_suppl.77","article-title":"LuCAB: A phase I\/II trial evaluating cabazitaxel in combination with [177 Lu]Lu-PSMA-617 in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)","volume":"41","author":"Kostos","year":"2023","journal-title":"J Clin Oncol"},{"issue":"16_suppl","key":"10.1016\/j.remnie.2025.500162_bib0100","doi-asserted-by":"crossref","first-page":"5005","DOI":"10.1200\/JCO.2023.41.16_suppl.5005","article-title":"LuPARP: Phase 1 trial of 177Lu-PSMA-617 and olaparib in patients with metastatic castration resistant prostate cancer (mCRPC)","volume":"41","author":"Sandhu","year":"2023","journal-title":"J Clin Oncol"},{"issue":"10459","key":"10.1016\/j.remnie.2025.500162_bib0105","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1016\/S0140-6736(24)01653-2","article-title":"177 Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor therapy for taxane-naive patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): a phase 3, randomised, controlled trial","volume":"404","author":"Morris","year":"2024","journal-title":"Lancet."},{"issue":"2","key":"10.1016\/j.remnie.2025.500162_bib0110","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijrobp.2024.07.1209","article-title":"PSMAddition: phase 3 trial of [177lu]Lu-PSMA-617 Plus Standard of Care (SoC) vs. soc alone in patients with metastatic hormone-sensitive prostate cancer","volume":"120","author":"Kim","year":"2024","journal-title":"Int J Radiat Oncol Biol Phys."},{"issue":"3","key":"10.1016\/j.remnie.2025.500162_bib0115","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.eururo.2023.08.026","article-title":"Administering [177Lu]Lu-PSMA-617 prior to radical prostatectomy in men with high-risk localised prostate cancer (LuTectomy): a single-centre, single-arm, phase 1\/2 study","volume":"85","author":"Eapen","year":"2024","journal-title":"Eur Urol."},{"issue":"11","key":"10.1016\/j.remnie.2025.500162_bib0120","doi-asserted-by":"crossref","first-page":"3465","DOI":"10.1007\/s00259-023-06281-6","article-title":"SUVmean on baseline [18F]PSMA-1007 PET and clinical parameters are associated with survival in prostate cancer patients scheduled for [177Lu]Lu-PSMA I&T","volume":"50","author":"Hartrampf","year":"2023","journal-title":"Eur J Nucl Med Mol Imaging."},{"issue":"16_suppl","key":"10.1016\/j.remnie.2025.500162_bib0125","doi-asserted-by":"crossref","first-page":"5027","DOI":"10.1200\/JCO.2022.40.16_suppl.5027","article-title":"Circulating tumour cells (CTCs) and PSMA PET correlates in the phase I PRINCE trial of 177Lu-PSMA-617 plus pembrolizumab for metastatic castration resistant prostate cancer (mCRPC)","volume":"40","author":"Hamid","year":"2022","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.remnie.2025.500162_bib0130","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.2967\/jnumed.121.262713","article-title":"Prostate-specific membrane antigen radioligand therapy using 177Lu-PSMA I&T and 177Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer: comparison of safety, biodistribution, and dosimetry","volume":"63","author":"Schuchardt","year":"2022","journal-title":"J Nucl Med."},{"issue":"6","key":"10.1016\/j.remnie.2025.500162_bib0135","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1016\/j.eururo.2018.11.016","article-title":"Treatment outcome, toxicity, and predictive factors for radioligand therapy with 177Lu-PSMA-I&T in metastatic castration-resistant prostate cancer","volume":"75","author":"Heck","year":"2019","journal-title":"Eur Urol."},{"key":"10.1016\/j.remnie.2025.500162_bib0140","doi-asserted-by":"crossref","DOI":"10.1016\/j.annonc.2022.07.1886","article-title":"1400P Efficacy and safety of 177Lu-PNT2002 prostate-specific membrane antigen (PSMA) therapy in metastatic castration resistant prostate cancer (mCRPC): Initial results from SPLASH","volume":"33","author":"Hansen","year":"2022","journal-title":"Ann Oncol."},{"key":"10.1016\/j.remnie.2025.500162_bib0145","doi-asserted-by":"crossref","DOI":"10.1177\/17588359231157632","article-title":"Status of PSMA-targeted radioligand therapy in prostate cancer: current data and future trials","volume":"15","author":"Jang","year":"2023","journal-title":"Ther Adv Med Oncol."},{"issue":"4","key":"10.1016\/j.remnie.2025.500162_bib0150","first-page":"634","article-title":"Pharmacokinetics and biodistribution of 111In- and 177Lu-labeled J591 antibody specific for prostate-specific membrane antigen: prediction of 90Y-J591 radiation dosimetry based on 111In or 177Lu?","volume":"46","author":"Vallabhajosula","year":"2005","journal-title":"J Nucl Med."},{"issue":"4","key":"10.1016\/j.remnie.2025.500162_bib0155","first-page":"227","article-title":"Prostate-specific membrane antigen\u2013targeted theranostics: past, present, and future approaches","volume":"20","author":"Hawkey","year":"2022","journal-title":"Clin Adv Hematol Oncol HO."},{"issue":"21","key":"10.1016\/j.remnie.2025.500162_bib0160","doi-asserted-by":"crossref","first-page":"4591","DOI":"10.1200\/JCO.2005.05.160","article-title":"Phase I trial of 177lutetium-labeled J591, a monoclonal antibody to prostate-specific membrane antigen, in patients with androgen-independent prostate cancer","volume":"23","author":"Bander","year":"2005","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol."},{"issue":"18","key":"10.1016\/j.remnie.2025.500162_bib0165","doi-asserted-by":"crossref","first-page":"5182","DOI":"10.1158\/1078-0432.CCR-13-0231","article-title":"Phase II study of lutetium-177\u2013labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for metastatic castration-resistant prostate cancer","volume":"19","author":"Tagawa","year":"2013","journal-title":"Clin Cancer Res."},{"issue":"15","key":"10.1016\/j.remnie.2025.500162_bib0170","doi-asserted-by":"crossref","first-page":"2561","DOI":"10.1002\/cncr.32072","article-title":"Phase 1\/2 study of fractionated dose lutetium-177\u2013labeled anti\u2013prostate-specific membrane antigen monoclonal antibody J591 (177Lu-J591) for metastatic castration-resistant prostate cancer","volume":"125","author":"Tagawa","year":"2019","journal-title":"Cancer."},{"issue":"4_suppl","key":"10.1016\/j.remnie.2025.500162_bib0175","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2024.42.4_suppl.TPS256","article-title":"ProstACT GLOBAL: A phase 3 study of best standard of care with and without 177Lu-DOTA-rosopatamab (TLX591) for patients with PSMA expressing metastatic castration-resistant prostate cancer progressing despite prior treatment with a novel androgen axis drug","volume":"42","author":"Hawkins","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.remnie.2025.500162_bib0180","doi-asserted-by":"crossref","unstructured":"Geoffrey Johnson et al. SECuRE: A dose escalation\/expansion study to assess the anti-tumor efficacy of 67Cu-SAR-bisPSMA in patients with metastatic castrate resistant prostate cancer. JCO 42, TPS5116-TPS5116(2024). DOI:10.1200\/JCO.2024.42.16_suppl.TPS5116.","DOI":"10.1200\/JCO.2024.42.16_suppl.TPS5116"},{"issue":"8","key":"10.1016\/j.remnie.2025.500162_bib0185","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1097\/MNM.0000000000001858","article-title":"A phase 2, single-arm trial evaluating 131I-PSMA-1095 targeted radioligand therapy for metastatic castration-resistant prostate cancer","volume":"45","author":"Liu","year":"2024","journal-title":"Nucl Med Commun."},{"issue":"6_suppl","key":"10.1016\/j.remnie.2025.500162_bib0190","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2021.39.6_suppl.48","volume":"39","author":"Sartor","year":"2021","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.remnie.2025.500162_bib0195","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1200\/JCO.23.00573","article-title":"Prostate-specific membrane antigen-targeting alpha emitter via antibody delivery for metastatic castration-resistant prostate cancer: a phase I dose-escalation study of 225Ac-J591","volume":"42","author":"Tagawa","year":"2024","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol."},{"issue":"8_Supplement","key":"10.1016\/j.remnie.2025.500162_bib0200","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.AM2023-CT014","article-title":"Abstract CT014: Phase I dose-escalation study of fractionated dose 225Ac J591 for metastatic castration resistant prostate cancer","volume":"83","author":"Nauseef","year":"2023","journal-title":"Cancer Res"},{"key":"10.1016\/j.remnie.2025.500162_bib0205","doi-asserted-by":"crossref","first-page":"S968","DOI":"10.1016\/j.annonc.2024.08.1687","article-title":"1606P Mature follow up of phase I dose finding trial of pembrolizumab (pembro) with AR inhibitors (ARI) and priming tumour-targeted radiation with anti-PSMA alpha emitter 225Ac-J591","volume":"35","author":"Holmes","year":"2024","journal-title":"Ann Oncol."},{"issue":"16_suppl","key":"10.1016\/j.remnie.2025.500162_bib0210","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2023.41.16_suppl.5018","article-title":"Phase I dose-escalation results of prostate-specific membrane antigen-targeted radionuclide therapy (PSMA-TRT) with alpha-radiolabeled antibody 225Ac-J591 and beta-radioligand 177Lu-PSMA I&T","volume":"41","author":"Tagawa","year":"2023","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.remnie.2025.500162_bib0215","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.2967\/jnumed.116.178673","article-title":"225Ac-PSMA-617 for PSMA-targeted \u03b1-radiation therapy of metastatic castration-resistant prostate cancer","volume":"57","author":"Kratochwil","year":"2016","journal-title":"J Nucl Med."},{"issue":"5","key":"10.1016\/j.remnie.2025.500162_bib0220","doi-asserted-by":"crossref","first-page":"795","DOI":"10.2967\/jnumed.117.203539","article-title":"Targeted \u03b1-therapy of metastatic castration-resistant prostate cancer with 225Ac-PSMA-617: swimmer-plot analysis suggests efficacy regarding duration of tumor control","volume":"59","author":"Kratochwil","year":"2018","journal-title":"J Nucl Med."},{"issue":"1","key":"10.1016\/j.remnie.2025.500162_bib0225","doi-asserted-by":"crossref","first-page":"62","DOI":"10.2967\/jnumed.119.229229","article-title":"Predictors of overall and disease-free survival in metastatic castration-resistant prostate cancer patients receiving 225 Ac-PSMA-617 radioligand therapy","volume":"61","author":"Sathekge","year":"2020","journal-title":"J Nucl Med."},{"issue":"20","key":"10.1016\/j.remnie.2025.500162_bib0230","doi-asserted-by":"crossref","first-page":"9364","DOI":"10.7150\/thno.48107","article-title":"Efficacy and safety of 225Ac-PSMA-617 targeted alpha therapy in metastatic castration-resistant Prostate Cancer patients","volume":"10","author":"Yadav","year":"2020","journal-title":"Theranostics."},{"issue":"5","key":"10.1016\/j.remnie.2025.500162_bib0235","doi-asserted-by":"crossref","first-page":"669","DOI":"10.2967\/jnumed.120.251017","article-title":"First clinical results for PSMA-targeted \u03b1-therapy using 225Ac-PSMA-I&T in advanced-mCRPC patients","volume":"62","author":"Zacherl","year":"2021","journal-title":"J Nucl Med."},{"issue":"7_Supplement","key":"10.1016\/j.remnie.2025.500162_bib0240","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.AM2024-CT224","article-title":"Abstract CT224: preliminary efficacy and safety results from the (TATCIST) trial: A PSMA-directed targeted alpha therapy with FPI-2265 (225Ac-PSMA-I&T) for the treatment of metastatic castration-resistant prostate cancer (mCRPC)","volume":"84","author":"Delpassand","year":"2024","journal-title":"Cancer Res"}],"container-title":["Revista Espa\u00f1ola de Medicina Nuclear e Imagen Molecular (English Edition)"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2253808925000643?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2253808925000643?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,8,29]],"date-time":"2025-08-29T01:56:49Z","timestamp":1756432609000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2253808925000643"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":48,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["S2253808925000643"],"URL":"https:\/\/doi.org\/10.1016\/j.remnie.2025.500162","relation":{},"ISSN":["2253-8089"],"issn-type":[{"value":"2253-8089","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Revolutionizing prostate cancer treatment: PSMA-targeted therapy in modern therapeutics","name":"articletitle","label":"Article Title"},{"value":"Revista Espa\u00f1ola de Medicina Nuclear e Imagen Molecular (English Edition)","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.remnie.2025.500162","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.remn.2025.500162","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Sociedad Espa\u00f1ola de Medicina Nuclear e Imagen Molecular. Published by Elsevier Espa\u00f1a, S.L.U. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"500162"}}